Growth Metrics

Genmab A (GMAB) Receivables - Other (2023 - 2025)

Historic Receivables - Other for Genmab A (GMAB) over the last 3 years, with Q4 2025 value amounting to $62.0 million.

  • Genmab A's Receivables - Other rose 2653.06% to $62.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $62.0 million, marking a year-over-year increase of 2653.06%. This contributed to the annual value of $62.0 million for FY2025, which is 2653.06% up from last year.
  • Latest data reveals that Genmab A reported Receivables - Other of $62.0 million as of Q4 2025, which was up 2653.06% from $49.0 million recorded in Q4 2024.
  • Genmab A's Receivables - Other's 5-year high stood at $62.0 million during Q4 2025, with a 5-year trough of $43.0 million in Q4 2023.
  • In the last 3 years, Genmab A's Receivables - Other had a median value of $49.0 million in 2024 and averaged $51.3 million.
  • Per our database at Business Quant, Genmab A's Receivables - Other skyrocketed by 1395.35% in 2024 and then surged by 2653.06% in 2025.
  • Genmab A's Receivables - Other (Quarter) stood at $43.0 million in 2023, then increased by 13.95% to $49.0 million in 2024, then increased by 26.53% to $62.0 million in 2025.
  • Its Receivables - Other was $62.0 million in Q4 2025, compared to $49.0 million in Q4 2024 and $43.0 million in Q4 2023.